C
Cheng Beng Goh
Publications - 1
Citations - 52
Cheng Beng Goh is an academic researcher. The author has contributed to research in topics: Internal medicine & Renal function. The author has an hindex of 1, co-authored 1 publications receiving 52 citations.
Papers
More filters
Journal ArticleDOI
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
Christoph Wanner,Jennifer B. Green,Sibylle Hauske,Parminder K. Judge,Kaitlin Mayne,Sarah Yoon Ai Ng,Emily L. Sammons,Doreen Zhu,Natalie Staplin,David Preiss,William M. Stevens,K Wallendszus,R. Dayanandan,Carol Knott,Michael D. Hill,Jonathan Emberson,Susanne Brenner,Vladimir Cejka,Alfred K. Cheung,Zhihong Liu,Jing Li,Pei-Shiuan Chen Chen,Lai Seong Hooi,Takashi Kadowaki,Masaomi Nangaku,Adeera Levin,David Z.I. Cherney,Roberto Pontremoli,Aldo P. Maggioni,Shinya Goto,Aiko Tomita,Rajat Deo,Katherine R. Tuttle,Jens Eilbracht,Stefan Hantel,Mark Hopley,Martin J Landray,Colin Baigent,Richard Haynes,William G. Herrington,Martina Brueckmann,Francisco Javier Rossello Lozano,Peter Sandercock,Rudy Bilous,Charles L. Herzog,Paul K. Whelton,Janet Wittes,Derrick A Bennett,A. Burke,Richard Brown,Lucy Fletcher,Hannah Gosling,Emily Harding,Ryonfa Lee,Kevin Murphy,Yanru Qiao,Rachel Raff,Hui Yu,Marcela Fajardo-Moser,Andrea Lorimer,Donata Lucci,Anita Hepditch,A. Axler,Da-ang Hao,Cheng Beng Goh,Sarojini Sivanandam,Akiko Hashimoto,Wakako Negoro,Mori Tomoko +68 more
TL;DR: The EMPA-KIDNEY trial is an international randomized, double-blind, placebo-controlled trial assessing whether empagliflozin 10 mg daily decreases the risk of kidney disease progression or cardiovascular death in people with CKD.